Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors

Jacqueline D. Peacock, Matthew G. Pridgeon, Elizabeth A. Tovar, Curt J. Essenburg, Megan Bowman, Zachary Madaj, Julie Koeman, Elissa A. Boguslawski, Jamie Grit, Rebecca D. Dodd, Vadim Khachaturov, Diana M. Cardona, Mark Chen, David G. Kirsch, Flavio Maina, Rosanna Dono, Mary E. Winn, Carrie R. Graveel, Matthew R. Steensma

Cancer Res (2018) 78 (13): 3672–3687.

https://doi.org/10.1158/0008-5472.CAN-17-3167

Published: 01 July 2018

View article titled, Genomic Status of <em>MET</em> Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors

Includes: Supplementary data

Journal Articles

Abstract 3022: MET and ERBB2 are coexpressed in ERBB2+ breast cancers and contribute to innate resistance.

Amanda Paulson, Erik Linklater, Bree Berghuis, Marianne Melnik, George Vande Woude, Carrie R. Graveel

Cancer Res (2013) 73 (8_Supplement): 3022.

https://doi.org/10.1158/1538-7445.AM2013-3022

Published: 15 April 2013

View article titled, Abstract 3022: MET and ERBB2 are coexpressed in ERBB2+ breast cancers and contribute to innate resistance.

Journal Articles

Abstract 4864: Targeting MET and ERBB2 signaling in aggressive breast cancers

Carrie R. Graveel, Amanda Paulson, Erik Linklater, Bree Berghuis, Kristin Feenstra, Marianne Melnik, George Vande Woude

Cancer Res (2012) 72 (8_Supplement): 4864.

https://doi.org/10.1158/1538-7445.AM2012-4864

Published: 15 April 2012

View article titled, Abstract 4864: Targeting MET and ERBB2 signaling in aggressive breast cancers

Journal Articles

Abstract 3256: Investigating the intrinsic signaling differences in MET- and ERBB2-driven breast cancers

Carrie R. Graveel, Jack D. DeGroot, Karl Dykema, Robert E. Sigler, Kyle A. Furge, George F. Vande Woude

Cancer Res (2010) 70 (8_Supplement): 3256.

https://doi.org/10.1158/1538-7445.AM10-3256

Published: 15 April 2010

View article titled, Abstract 3256: Investigating the intrinsic signaling differences in MET- and ERBB2-driven breast cancers

Journal Articles

Tumorigenic effects of activating Met mutations in a knock-in mouse model

Carrie R. Graveel, Yanli Su, Ling-Mei Wang, Michele Fiscella, Lino Tessarollo, Carmen Birchmeier, Roderick T. Bronson, George F. Vande Woude

Cancer Res (2004) 64 (7_Supplement): 1177.

Published: 01 April 2004

View article titled, Tumorigenic effects of activating Met mutations in a knock-in mouse model

NARROW

Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors

Abstract 3022: MET and ERBB2 are coexpressed in ERBB2+ breast cancers and contribute to innate resistance.

Abstract 4864: Targeting MET and ERBB2 signaling in aggressive breast cancers

Abstract 3256: Investigating the intrinsic signaling differences in MET- and ERBB2-driven breast cancers

Tumorigenic effects of activating Met mutations in a knock-in mouse model

Email alerts

AACR Journals

Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors

Abstract 3022: MET and ERBB2 are coexpressed in ERBB2+ breast cancers and contribute to innate resistance.

Abstract 4864: Targeting MET and ERBB2 signaling in aggressive breast cancers

Abstract 3256: Investigating the intrinsic signaling differences in MET- and ERBB2-driven breast cancers

Tumorigenic effects of activating Met mutations in a knock-in mouse model

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only